• français
    • English
  • English 
    • français
    • English
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.
BIRD Home

Browse

This CollectionBy Issue DateAuthorsTitlesSubjectsJournals BIRDResearch centres & CollectionsBy Issue DateAuthorsTitlesSubjectsJournals

My Account

Login

Statistics

View Usage Statistics

Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing?

Thumbnail
Date
2013
Dewey
Economie sociale
Sujet
Health Administration; Health Economics; Quality of Life Research; Pharmacoeconomics and Health Outcomes
JEL code
I.I1.I18; I.I1.I11
Journal issue
PharmacoEconomics
Volume
31
Number
4
Publication date
2013
Article pages
335-343
Publisher
Springer
DOI
http://dx.doi.org/10.1007/s40273-013-0039-4
URI
https://basepub.dauphine.fr/handle/123456789/11177
Collections
  • LEDa : Publications
Metadata
Show full item record
Author
Degrassat-Théas, Albane
status unknown
Paubel, Pascal
247290 Institut Droit et Santé [IDS - U1145]
Parent de Curzon, Olivier
status unknown
Le Pen, Claude
status unknown
Sinègre, Martine
status unknown
Type
Article accepté pour publication ou publié
Abstract (EN)
Background To reach the French market, a new drug requires a marketing authorization (MA) and price and reimbursement agreements. These hurdles could delay access to new and promising drugs. Since 1992, French law authorizes the use of unlicensed drugs on an exceptional and temporary basis through a compassionate-use programme, known as Temporary Authorization for Use (ATU). This programme was implemented to improve early access to drugs under development or authorized abroad. However, it is suspected to be inflationary, bypassing public bodies in charge of health technology assessment (HTA) and of pricing. Objective The aim of this study is to observe the market access after the formal licensing of drugs that went through this compassionate-use programme. Methods We included all ATUs that received an MA between 1 January 2005 and 30 June 2010. We first examined market access delays from these drugs using the standard administrative path. We positioned this result in relation to launch delays observed in France (for all outpatient drugs) and in other major European markets. Second, we assessed the bargaining power of a hospital purchaser after those drugs had obtained an MA by calculating the price growth rate after the approval. Results During the study period, 77 ATUs were formally licensed. The study concluded that, from the patient’s perspective, licensing and public bodies’ review time was shortened by a combined total of 36 months. The projected 11-month review time of public bodies may be longer than delays usually observed for outpatient drugs. Nonetheless, the study revealed significant benefits for French patient access based on comparable processing to launch time with those of other European countries with tight price control policies. In return, a 12 % premium, on average, is paid to pharmaceutical companies while drugs are under this status (sub-analysis on 56 drugs). Conclusions In many instances, the ATU programme responds to a public health need by accelerating the availability of new drugs even though this study suggests an impact of the programme on the market access of these drugs for which the standard administrative path is longer than usual. In addition, pharmaceutical companies seem to market compassionate-use drugs with a presumed benefit/risk ratio at a price that guarantees a margin for future negotiation.

  • Accueil Bibliothèque
  • Site de l'Université Paris-Dauphine
  • Contact
SCD Paris Dauphine - Place du Maréchal de Lattre de Tassigny 75775 Paris Cedex 16

 Content on this site is licensed under a Creative Commons 2.0 France (CC BY-NC-ND 2.0) license.